Using this cutoff, antithrombin antibodies were present in 10 of the patients in the APS group and 5 of the patients in the SLE/aPL+ group (38.5%), compared to only 1 patient in the SLE/aPL− group (6%). The gene discussed is FASLG; the disease is systemic lupus erythematosus.